TBnet webinar
Today, 29 August at 17:00 CEST the NTMnet webinar entitled "Therapeutic drug monitoring in nontuberculous mycobacterial disease: what you need to know?"
More information and free registration:
TBnet Annual Meeting
We are looking forward to welcoming as many TBnet members as possible at our TBnet Annual Meeting 2024 in beautiful Vienna, Austria, on Friday, 6 September, just before the ERS Congress.
Due to limited space in the Klinik Penzing that is hosting us this year, the registration for the onsite attendance is now closed.
But you can still register for an online participation via Zoom. Please register here:
The agenda of the meeting is available for download here:
Winners of the TBnet photo competition "Moments of Hope"
Thank you to everyone who participated in this contest by submitting photos that powerfully and humbly illustrated “Moments of Hope” – the impact of TB on people’s lives today. Thanks to everyone who voted in this contest, and we especially want to thank the people in the photos.
In this and the next two issues of TBnet News we will be using the winning photos as a cover.
Please visit our social media to find out who has won the third, second, and, of course, the first place in the competition!
UNITE4TB webinar
Expert interview: Management of adverse events in TB care
26 September 2024 at 13:00-14:00 CEST
Speaker: Dr Simon Tiberi (GSK, UK)
More information and registration: https://www.unite4tb.org/newsroom/unite4tb-webinar-management-adverse-events-tb-care
Essential TB read
In the last couple of weeks, two important documents have been released by the World Health Organization:
Target product profile (TPP) for tuberculosis diagnosis and detection of drug resistance. The document consolidates two TPPs for TB diagnostics to be carried out at the peripheral level: a newly updated TPP for a rapid test for TB detection and a TPP released in 2021 on next-generation DST for Mycobacterium tuberculosis. The updated and consolidated TPPs introduces, for the first time, definitions of classes of point-of-care (POC) tests and near-POC tests, and it relates these to the class of low-complexity diagnostic technologies currently recommended.
Key updates to the treatment of drug-resistant tuberculosis: rapid communication. The WHO now recommends four new treatment regimens for the treatment of MDR/RR-TB and pre-XDR-TB: one 6-month BDLLfxC regimen and three 9-months, all-oral regimens: BLMZ, BLLfxCZ and BDLLfxZ. This is a great step towards more efficacious and safe treatment of drug-resistant forms of tuberculosis.
TBnet News
Editor – Irina Kontsevaya
Layout & formatting – Liga Rusmane
Cover picture – Charles Quist
Comments